Bai Qiang, Chen Fang, Qi Juan, Chen Jian-hua, Wang Yi-xin
Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200092, China.
Zhonghua Nan Ke Xue. 2007 May;13(5):414-6.
To detect HER-2/neu expression in prostate cancer tissues of both androgen dependent and independent groups and to evaluate the role of HER-2/neu in androgen independent prostate cancer.
Immunohistochemical assay was used in the detection of HER-2/neu in the prostate cancer samples from 30 cases of androgen dependent cancer and 24 cases of androgen independent cancer. The correlation was analyzed between HER-2/neu over-expression and the tumor's clinical stage and Gleason score.
The rates of HER-2/neu over-expression were 10% and 33% in the androgen dependent group and the androgen independent group, significantly higher in the Gleason score >7 group and the clinical stage > T2 group than in the -7 group and the > T2 group (14.29% vs. 26.92%, 34.62% vs. 7.14%, P < 0.01).
The rate of HER-2/neu over-expression is high in androgen independent prostate cancer and is correlated with the tumor stage and Gleason score.
检测雄激素依赖型和非依赖型前列腺癌组织中HER-2/neu的表达情况，评估HER-2/neu在雄激素非依赖型前列腺癌中的作用。
采用免疫组织化学法检测30例雄激素依赖型前列腺癌和24例雄激素非依赖型前列腺癌样本中的HER-2/neu。分析HER-2/neu过表达与肿瘤临床分期和Gleason评分之间的相关性。
雄激素依赖组和非依赖组中HER-2/neu过表达率分别为10%和33%，Gleason评分>7组和临床分期>T2组显著高于Gleason评分≤7组和临床分期≤T2组（14.29%对26.92%，34.62%对7.14%，P<0.01）。
雄激素非依赖型前列腺癌中HER-2/neu过表达率较高，且与肿瘤分期和Gleason评分相关。
